

# Michael A Quinn

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7513197/michael-a-quinn-publications-by-year.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

160  
papers

8,409  
citations

46  
h-index

89  
g-index

169  
ext. papers

9,511  
ext. citations

5.1  
avg. IF

5.54  
L-index

#	Paper	IF	Citations
160	Reaching the women with the greatest needs: Two models for initiation and scale-up of gynecologic oncology fellowship trainings in low-resource settings. <i>International Journal of Gynecology and Obstetrics</i> , <b>2021</b> , 155 Suppl 1, 115-122	4	0
159	The IGCS global curriculum mentorship and training program: building human capacity for gynecologic cancer treatment and research where the need is greatest. <i>International Journal of Gynecological Cancer</i> , <b>2021</b> , 31, 1380-1381	3.5	1
158	Informing American Muslims about living donation through tailored health education: A randomized controlled crossover trial evaluating increase in biomedical and religious knowledge. <i>American Journal of Transplantation</i> , <b>2021</b> , 21, 1227-1237	8.7	3
157	The impact of religiously tailored and ethically balanced education on intention for living organ donation among Muslim Americans. <i>Clinical Transplantation</i> , <b>2020</b> , 34, e14111	3.8	3
156	Improving response to progestin treatment of low-grade endometrial cancer. <i>International Journal of Gynecological Cancer</i> , <b>2020</b> , 30, 1811-1823	3.5	8
155	Renal Replacement Knowledge and Preferences for African Americans With Chronic Kidney Disease. <i>Journal of Renal Care</i> , <b>2020</b> , 46, 151-160	1.6	4
154	Management and long-term outcomes of women with adenocarcinoma in situ of the cervix: A retrospective study. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , <b>2020</b> , 60, 123-129	1.7	2
153	COVID 19 vaccination lessons from Japanese anti-HPV vaccination lobby. <i>International Journal of Gynecological Cancer</i> , <b>2020</b> , 30, 1255	3.5	0
152	Two viral infections in Japan. <i>International Journal of Gynecological Cancer</i> , <b>2020</b> , 30, 1258-1259	3.5	0
151	The Development and Validation of the Islamic Knowledge of Living Organ Donation Knowledge Scale for Measuring Organ Donation Knowledge Among Muslim Communities. <i>Progress in Transplantation</i> , <b>2020</b> , 30, 315-321	1.1	4
150	Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE Study.. <i>JCO Precision Oncology</i> , <b>2019</b> , 3, 1-18	3.6	
149	Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 295-309	21.7	263
148	Endometrial cancer risk and survival by tumor MMR status. <i>Journal of Gynecologic Oncology</i> , <b>2018</b> , 29, e39	4	19
147	Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities. <i>Current Medicinal Chemistry</i> , <b>2018</b> , 25, 4785-4806	4.3	44
146	The Prevalence, Incidence, and Quality-of-Life Impact of Lymphedema After Treatment for Vulvar or Vaginal Cancer. <i>Rehabilitation Oncology</i> , <b>2018</b> , 36, 48-55	0.8	1
145	Lymphedema following gynecological cancer: Results from a prospective, longitudinal cohort study on prevalence, incidence and risk factors. <i>Gynecologic Oncology</i> , <b>2017</b> , 146, 623-629	4.9	59
144	Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference. <i>Journal of Gynecologic Oncology</i> , <b>2017</b> , 28, e54	4	12

143	Family history of cancer predicts endometrial cancer risk independently of Lynch Syndrome: Implications for genetic counselling. <i>Gynecologic Oncology</i> , <b>2017</b> , 147, 381-387	4.9	21
142	HPV genotype-specific concordance between EuroArray HPV, Anyplex II HPV28 and Linear Array HPV Genotyping test in Australian cervical samples. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , <b>2017</b> , 4, 79-84	4.6	7
141	Interleukin 6 Present in Inflammatory Ascites from Advanced Epithelial Ovarian Cancer Patients Promotes Tumor Necrosis Factor Receptor 2-Expressing Regulatory T Cells. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1482	8.4	34
140	Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer - a population-based study. <i>Acta Oncologica</i> , <b>2016</b> , 55, 226-33	3.2	12
139	Coalition of Oct4A and $\beta$ integrins in facilitating metastasis in ovarian cancer. <i>BMC Cancer</i> , <b>2016</b> , 16, 432	4.8	5
138	Oral cyclophosphamide in recurrent ovarian cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2016</b> , 12, e154-60	1.9	18
137	Low dose cyclophosphamide: Mechanisms of T cell modulation. <i>Cancer Treatment Reviews</i> , <b>2016</b> , 42, 3-9	14.4	81
136	Predictors of depression and anxiety symptom trajectories in the 24 months following diagnosis of breast or gynaecologic cancer. <i>Breast</i> , <b>2016</b> , 26, 100-5	3.6	18
135	Findings and Outcomes in a Prevacination Cohort of Women Younger Than 25 Years Attending a Tertiary Colposcopy Service. <i>Journal of Lower Genital Tract Disease</i> , <b>2016</b> , 20, 224-9	3.6	1
134	Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. <i>Lancet Oncology</i> , <b>2015</b> , 16, 928-36	21.7	475
133	A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer. <i>Molecular Cancer</i> , <b>2015</b> , 14, 152	42.1	25
132	Comparison of the Roche Cobas( ) 4800 HPV assay to Digene Hybrid Capture 2, Roche Linear Array and Roche Amplicor for Detection of High-Risk Human Papillomavirus Genotypes in Women undergoing treatment for cervical dysplasia. <i>Journal of Clinical Virology</i> , <b>2015</b> , 62, 63-5	14.5	19
131	Evaluation of p16INK4a immunostaining for the detection of high-grade changes in cervical cytology. <i>Pathology</i> , <b>2015</b> , 47, 314-9	1.6	2
130	Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer. <i>BioMed Research International</i> , <b>2015</b> , 2015, 413076	3	143
129	Whole-genome characterization of chemoresistant ovarian cancer. <i>Nature</i> , <b>2015</b> , 521, 489-94	50.4	890
128	Incidence, risk factors and estimates of a woman's risk of developing secondary lower limb lymphedema and lymphedema-specific supportive care needs in women treated for endometrial cancer. <i>Gynecologic Oncology</i> , <b>2015</b> , 136, 87-93	4.9	81
127	Anxiety and depression symptoms in the 2 years following diagnosis of breast or gynaecologic cancer: prevalence, course and determinants of outcome. <i>Supportive Care in Cancer</i> , <b>2015</b> , 23, 2215-24	3.9	46
126	Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 90-100	2.2	149

125	Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlations. <i>Journal of Translational Medicine</i> , <b>2014</b> , 12, 179	8.5	12
124	A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer <b>2014</b> , 2, 16		21
123	Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden. <i>BMC Cancer</i> , <b>2014</b> , 14, 317	4.8	83
122	Comparison of the hospital anxiety and depression scale and the center for epidemiological studies depression scale for detecting depression in women with breast or gynecologic cancer. <i>General Hospital Psychiatry</i> , <b>2014</b> , 36, 74-80	5.6	22
121	Serum HE4 as a prognostic marker in endometrial cancer--a population based study. <i>Gynecologic Oncology</i> , <b>2014</b> , 132, 159-65	4.9	72
120	Survival of Australian women with invasive epithelial ovarian cancer: a population-based study. <i>Medical Journal of Australia</i> , <b>2014</b> , 201, 283-8	4	44
119	Reply to J. Moline et al. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2278-9	2.2	3
118	Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden. <i>Frontiers in Oncology</i> , <b>2014</b> , 4, 75	5.3	44
117	Prognostic significance of steroid receptor positivity and adjuvant progestogen use in endometrial stromal sarcoma. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , <b>2014</b> , 54, 453-6	1.7	4
116	Identification of patients with persistent trophoblastic disease after complete hydatidiform mole by using a normal 24-hour urine hCG regression curve. <i>Gynecologic Oncology</i> , <b>2014</b> , 133, 542-5	4.9	4
115	Quality of life of women with lower limb swelling or lymphedema 3-5 years following endometrial cancer. <i>Gynecologic Oncology</i> , <b>2014</b> , 133, 314-8	4.9	43
114	Hereditary gynecologic cancers. <i>International Journal of Gynecology and Obstetrics</i> , <b>2014</b> , 124, 189-92	4	12
113	A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: Outback (ANZGOG0902/GOG0274/RTOG1174).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS5632-TPS5632	2.2	10
112	The REZOLVE phase II trial to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced, chemotherapy-resistant ovarian cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS5627-TPS5627	2.2	1
111	The PARAGON phase 2 trial of anastrozole in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS5621-TPS5621	2.2	
110	Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden. <i>Molecular Cancer</i> , <b>2013</b> , 12, 24	42.1	147
109	Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. <i>Journal of Cellular Biochemistry</i> , <b>2013</b> , 114, 21-34	4.7	73
108	Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment. <i>Clinical Immunology</i> , <b>2013</b> , 149, 97-110	9	80

107	Hybrid Capture II testing for high-risk human papillomavirus DNA in the follow-up of women treated for high-grade cervical intraepithelial neoplasia. <i>Journal of Lower Genital Tract Disease</i> , <b>2013</b> , 17, 308-14	3.6	5
106	Long-term outcomes after progestogen treatment for early endometrial cancer. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , <b>2013</b> , 53, 566-70	1.7	7
105	Screening for depression and anxiety in women with breast and gynaecologic cancer: course and prevalence of morbidity over 12 months. <i>Psycho-Oncology</i> , <b>2013</b> , 22, 2071-8	3.9	47
104	Nomogram to predict the probability of relapse in patients diagnosed with borderline ovarian tumors. <i>International Journal of Gynecological Cancer</i> , <b>2013</b> , 23, 264-7	3.5	14
103	PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms: ANZGOG 0903.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS5614-TPS5614	3.2	7
102	Endometrial cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , <b>2012</b> , 26, 311-24	4.6	45
101	Prognostic value of elevated preoperative serum CA125 in ovarian tumors of low malignant potential: a multinational collaborative study (ANZGOG0801). <i>Gynecologic Oncology</i> , <b>2012</b> , 126, 36-40	4.9	25
100	Attributes of Oct4 in stem cell biology: perspectives on cancer stem cells of the ovary. <i>Journal of Ovarian Research</i> , <b>2012</b> , 5, 37	5.5	45
99	Substantially modified ratios of effector to regulatory T cells during chemotherapy in ovarian cancer patients return to pre-treatment levels at completion: implications for immunotherapy. <i>Cancers</i> , <b>2012</b> , 4, 581-600	6.6	10
98	Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. <i>PLoS ONE</i> , <b>2012</b> , 7, e46858	3.7	154
97	LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. <i>Cancer Research</i> , <b>2012</b> , 72, 4060-73	10.1	73
96	2D-PAGE of ovarian cancer: analysis of soluble and insoluble fractions using medium-range immobilized pH gradients. <i>Biochemical and Biophysical Research Communications</i> , <b>2011</b> , 406, 408-13	3.4	23
95	Clearance of Human Papillomavirus in Women Treated for Cervical Dysplasia. <i>Obstetrics and Gynecology</i> , <b>2011</b> , 118, 166	4.9	1
94	First-line therapy in ovarian cancer trials. <i>International Journal of Gynecological Cancer</i> , <b>2011</b> , 21, 756-62	3.5	75
93	A response to the forgotten fallopian tube. <i>Nature Reviews Cancer</i> , <b>2011</b> , 11, 227-227	3.3	
92	Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. <i>Journal of Cellular Biochemistry</i> , <b>2011</b> , 112, 2850-64	4.7	173
91	Clearance of human papillomavirus in women treated for cervical dysplasia. <i>Obstetrics and Gynecology</i> , <b>2011</b> , 117, 101-108	4.9	16
90	Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIg). <i>International Journal of Gynecological Cancer</i> , <b>2011</b> , 21, 419-23	3.5	400

89	Transabdominal cervical cerclage. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , <b>2010</b> , 50, 460-4	1.7	21
88	Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009. <i>International Journal of Gynecological Cancer</i> , <b>2010</b> , 20, 1290-8	3.5	7
87	Malignant transformation within ovarian dermoid cysts: an audit of treatment received and patient outcomes. an Australia New Zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIG) study. <i>International Journal of Gynecological Cancer</i> , <b>2010</b> , 20, 75-81	3.5	13
86	Neuronal transcription factor Brn-3a(l) is over expressed in high-grade ovarian carcinomas and tumor cells from ascites of patients with advanced-stage ovarian cancer. <i>Journal of Ovarian Research</i> , <b>2010</b> , 3, 17	5.5	7
85	Predictive value of magnetic resonance imaging in assessing myometrial invasion in endometrial cancer: is radiological staging sufficient for planning conservative treatment?. <i>International Journal of Gynecological Cancer</i> , <b>2010</b> , 20, 1166-9	3.5	21
84	Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. <i>Current Cancer Drug Targets</i> , <b>2010</b> , 10, 268-78	2.8	178
83	HPV genotype prevalence in women with abnormal pap smears in Melbourne, Australia. <i>Journal of Medical Virology</i> , <b>2009</b> , 81, 1283-91	19.7	32
82	Complex endometrial hyperplasia in the context of tibolone administration. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , <b>2009</b> , 49, 338-9	1.7	0
81	Outcome in women with no endocervical component on cervical cytology after treatment for high-grade cervical dysplasia. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , <b>2009</b> , 49, 426-8	1.7	10
80	CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool?. <i>Journal of Translational Medicine</i> , <b>2009</b> , 7, 102	8.5	67
79	Hormonal therapies and gynaecological cancers. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , <b>2008</b> , 22, 407-21	4.6	31
78	Epidemiology and prevention of cervical cancer in Indonesia, Malaysia, the Philippines, Thailand and Vietnam. <i>Vaccine</i> , <b>2008</b> , 26 Suppl 12, M71-9	4.1	55
77	Does experience in colposcopy improve identification of high grade abnormalities?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , <b>2008</b> , 141, 75-8	2.4	30
76	Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. <i>International Journal of Cancer</i> , <b>2007</b> , 120, 2426-34	7.5	143
75	Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. <i>Journal of Cellular Physiology</i> , <b>2007</b> , 213, 581-8	7	192
74	A new prognostic model for FIGO stage 1 epithelial ovarian cancer. <i>Gynecologic Oncology</i> , <b>2007</b> , 104, 607-11	4.9	24
73	Treatment of microinvasive adenocarcinoma of the uterine cervix: a retrospective study and review of the literature. <i>Gynecologic Oncology</i> , <b>2007</b> , 107, 424-30	4.9	77
72	Proteomic Profiling of Ovarian Cancer Plasma using Immunoaffinity Depleted Plasma and Two-Dimensional PAGE. <i>Clinical Proteomics</i> , <b>2007</b> , 3, 22-29	5	2

71	Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. <i>Journal of Carcinogenesis</i> , <b>2007</b> , 6, 11	1.9	92
70	Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results. <i>Journal of Clinical Microbiology</i> , <b>2007</b> , 45, 2130-7	9.7	73
69	Genistein-induced proteome changes in the human endometrial carcinoma cell line, ishikawa. <i>Clinical Proteomics</i> , <b>2006</b> , 2, 153-167	5	2
68	The impact of PET/CT in the management of recurrent ovarian cancer. <i>Gynecologic Oncology</i> , <b>2006</b> , 103, 271-6	4.9	110
67	Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium. <i>American Journal of Physiology - Cell Physiology</i> , <b>2006</b> , 290, C1532-42	5.4	157
66	CHAPTER 11 How to manage and communicate with patients about HPV?. <i>International Journal of Gynecology and Obstetrics</i> , <b>2006</b> , 94 Suppl 1, S106-S112	4	4
65	Chapter 8: Screening for cervical cancer in developing countries. <i>Vaccine</i> , <b>2006</b> , 24 Suppl 3, S3/71-7	4.1	188
64	A three-dimensional multivariate image processing technique for the analysis of FTIR spectroscopic images of multiple tissue sections. <i>BMC Medical Imaging</i> , <b>2006</b> , 6, 12	2.9	44
63	Complementary medicine use by Australian women with gynaecological cancer. <i>Psycho-Oncology</i> , <b>2006</b> , 15, 209-20	3.9	17
62	Treatment decisions: a qualitative study with women with gynaecological cancer. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , <b>2006</b> , 46, 46-8	1.7	4
61	Guidelines following hydatidiform mole: a reappraisal. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , <b>2006</b> , 46, 112-8	1.7	13
60	Persistent trophoblast disease following partial molar pregnancy. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , <b>2006</b> , 46, 119-23	1.7	39
59	Is colposcopy needed following laser ablation for dysplasia?. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , <b>2006</b> , 46, 375-8	1.7	
58	An alternative cost effectiveness analysis of ThinPrep in the Australian setting. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , <b>2005</b> , 45, 289-94	1.7	9
57	Should the Pap smear be repeated at the first colposcopy visit?. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , <b>2005</b> , 45, 514-7	1.7	4
56	"Like roulette": Australian women's explanations of gynecological cancers. <i>Social Science and Medicine</i> , <b>2005</b> , 61, 323-32	5.1	20
55	Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. <i>Clinical and Experimental Metastasis</i> , <b>2005</b> , 22, 391-402	4.7	104
54	Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer. <i>Proteomics</i> , <b>2005</b> , 5, 4625-36	4.8	82

53	Infrared imaging of normal and diseased cervical tissue sections <b>2005</b> ,		5
52	A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 1890-8	12.9	80
51	Multidisciplinary care for women with early breast cancer in the Australian context. <i>Medical Journal of Australia</i> , <b>2004</b> , 180, 429-430		4
50	Cell-free 59 kDa immunoreactive integrin-linked kinase: a novel marker for ovarian carcinoma. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 2415-20	12.9	41
49	Expression and localization of alphavbeta6 integrin in extraplacental fetal membranes: possible role in human parturition. <i>Molecular Human Reproduction</i> , <b>2004</b> , 10, 173-9	4.4	10
48	Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). <i>Journal of the National Cancer Institute</i> , <b>2004</b> , 96, 487-8	9.7	221
47	Women with low-grade abnormalities on Pap smear should be referred for colposcopy. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , <b>2004</b> , 44, 252-5	1.7	4
46	Benign endocervical cystic glandular change mimicking minimal deviation adenocarcinoma of the cervix on magnetic resonance imaging: a case report. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , <b>2004</b> , 44, 358-9	1.7	1
45	Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression. <i>Gynecologic Oncology</i> , <b>2004</b> , 92, 80-8	4.9	24
44	A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer. <i>Gynecologic Oncology</i> , <b>2004</b> , 93, 417-21	4.9	20
43	Embodied changes and the search for gynecological cancer diagnosis. <i>Medical Anthropology Quarterly</i> , <b>2004</b> , 18, 376-96	2.5	21
42	Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. <i>Vaccine</i> , <b>2004</b> , 23, 172-81	4.1	135
41	'He's telling us something'. <i>Anthropology and Medicine</i> , <b>2004</b> , 11, 327-41	1.1	11
40	Fourier Transform Infrared Imaging and Unsupervised Hierarchical Clustering Applied to Cervical Biopsies. <i>Australian Journal of Chemistry</i> , <b>2004</b> , 57, 1139	1.2	24
39	Cervical screening in the 21st century. <i>Journal of the Medical Association of Thailand = Chotmaiht Thangphaet</i> , <b>2004</b> , 87 Suppl 3, S94-5		1
38	Detection of endometrial cancer by determination of matrix metalloproteinases in the uterine cavity. <i>Gynecologic Oncology</i> , <b>2003</b> , 90, 318-24	4.9	22
37	Mutation analysis of CDP, TP53, and KRAS in uterine leiomyomas. <i>Molecular Carcinogenesis</i> , <b>2003</b> , 37, 61-4	5	14
36	Removal of blood components from cervical smears: implications for cancer diagnosis using FTIR spectroscopy. <i>Biopolymers</i> , <b>2003</b> , 72, 69-76	2.2	27



35	An approach to remove albumin for the proteomic analysis of low abundance biomarkers in human serum. <i>Proteomics</i> , <b>2003</b> , 3, 1980-7	4.8	178
34	Proteomic profiling of proteins associated with urokinase plasminogen activator receptor in a colon cancer cell line using an antisense approach. <i>Proteomics</i> , <b>2003</b> , 3, 288-98	4.8	21
33	Integrin-linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid. <i>Journal of Pathology</i> , <b>2003</b> , 201, 229-37	9.4	111
32	Screening and prevention of gynaecological cancer. <i>Reviews in Gynaecological Practice</i> , <b>2003</b> , 3, 148-155		
31	Cotyledonoid dissecting leiomyoma. <i>Pathology</i> , <b>2003</b> , 35, 177-179	1.6	3
30	Screening the high risk patient for gynaecological cancer. <i>Yonsei Medical Journal</i> , <b>2002</b> , 43, 717-21	3	1
29	Influence of benign cellular changes in diagnosis of cervical cancer using IR microspectroscopy. <i>Biopolymers</i> , <b>2002</b> , 67, 362-6	2.2	20
28	Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. <i>Cancer</i> , <b>2002</b> , 94, 1466-75	6.4	111
27	Association between alphavbeta6 integrin expression, elevated p42/44 kDa MAPK, and plasminogen-dependent matrix degradation in ovarian cancer. <i>Journal of Cellular Biochemistry</i> , <b>2002</b> , 84, 675-86	4.7	49
26	Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer. <i>Journal of Histochemistry and Cytochemistry</i> , <b>2002</b> , 50, 1371-80	3.4	86
25	Ovarian cancer: patterns of care in Victoria during 1993-1995. <i>Medical Journal of Australia</i> , <b>2002</b> , 177, 11-6	4	32
24	Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study. <i>Gynecologic Oncology</i> , <b>2001</b> , 81, 216-24	4.9	8
23	Characteristics of ovarian and uterine cancers in a cohort of in vitro fertilization patients. <i>Gynecologic Oncology</i> , <b>2001</b> , 82, 64-8	4.9	31
22	Adenocarcinoma in situ of the uterine cervix: an experience with 100 cases. <i>Gynecologic Oncology</i> , <b>2000</b> , 79, 207-10	4.9	93
21	Hormonal treatment of endometrial cancer. <i>Hematology/Oncology Clinics of North America</i> , <b>1999</b> , 13, 163-87, ix	3.1	8
20	A phase II trial of carboplatin and etoposide for relapsed or metastatic carcinoma of the cervix. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , <b>1998</b> , 38, 87-90	1.7	2
19	FTIR microspectroscopic study of cell types and potential confounding variables in screening for cervical malignancies <b>1998</b> , 4, 75-91		137
18	An investigation into FTIR spectroscopy as a biodiagnostic tool for cervical cancer. <i>Biospectroscopy</i> , <b>1998</b> , 2, 143-153		84

17	FTIR microspectroscopic study of cell types and potential confounding variables in screening for cervical malignancies <b>1998</b> , 4, 75		2
16	A clinicopathologic study of glandular dysplasia of the cervix. <i>Gynecologic Oncology</i> , <b>1997</b> , 64, 166-70	4.9	29
15	Microinvasive adenocarcinoma of the cervix: a clinicopathologic study of 77 women. <i>Obstetrics and Gynecology</i> , <b>1997</b> , 89, 88-93	4.9	65
14	Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. Survey of Women's Health Study Group. <i>International Journal of Cancer</i> , <b>1997</b> , 71, 948-51	7.5	121
13	Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer <b>1997</b> , 71, 948		9
12	Is there any value in bimanual pelvic examination as a screening test?. <i>Medical Journal of Australia</i> , <b>1995</b> , 162, 408-410	4	41
11	Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Survey of Women's Health Study Group. <i>International Journal of Cancer</i> , <b>1995</b> , 62, 678-84	7.5	205
10	Southern blot and dot blot hybridisation compared to PCR for the detection of human papillomavirus DNA in biopsies of the uterine cervix from women with dysplasia. <i>Clinical and Diagnostic Virology</i> , <b>1993</b> , 1, 187-94		1
9	Women with a pelvic mass--when to perform an ultrasound. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , <b>1993</b> , 33, 404-7	1.7	5
8	The absence of genital human papillomavirus DNA in virginal women. <i>International Journal of STD and AIDS</i> , <b>1992</b> , 3, 414-7	1.4	44
7	Collision tumor: serous adenocarcinoma and steroid cell tumor of the ovary. <i>Pathology</i> , <b>1992</b> , 24, 60-2	1.6	22
6	Labour induction with low dose PGE2 vaginal gel: result of an Australian multicentre randomized trial. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , <b>1989</b> , 29, 124-8	1.7	14
5	Fetal intravascular transfusion for severe erythroblastosis: effects on haematology and survival. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , <b>1986</b> , 26, 192-5	1.7	4
4	Curarisation of fetus for intrauterine procedures. <i>Lancet, The</i> , <b>1985</b> , 1, 1164	4.0	15
3	Phase II trial of VP-16-213 in advanced ovarian carcinoma. <i>Gynecologic Oncology</i> , <b>1985</b> , 22, 162-6	4.9	25
2	"Spurious" labour - does it matter?. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , <b>1981</b> , 21, 167-9	1.7	4
1	Study Protocol for Informing American Muslims about Organ Donation (I AM a LD) <b>2011</b> , 1-17		7